nga Swedish research-intensive companies that are developing treatments for rare diseases and that have great potential to make a difference for patients who today may be more or less without adequate treatment. Since 2000, 107 orphan drug designations have been granted to Swedish companies by the US and European Commission. the European Medicines Agency.
– “Investors, especially from the US, are asking for rare disease projects and therefore we have now chosen, together with Business Sweden, to produce a focused material to disseminate both at international meetings and digitally,” says Sara Gunnerås, report manager at SwedenBIO.
This type of niche material aimed at an international audience is in line with SwedenBIO’s outreach efforts to promote Sweden as a strong life science nation. The brochure interviews SOBI, Immedica Pharma, HealthCap, NDA Group and Karolinska Institutet. You can find the brochure here.
